Does Diltiazem Lower Heart Rate? How It Works

Diltiazem reliably lowers heart rate by blocking calcium channels in the heart, slowing electrical conduction through the atrioventricular (AV) node. It belongs to a class of drugs called non-dihydropyridine calcium channel blockers, and rate control is one of its primary clinical purposes. The degree to which it slows the heart depends on the dose, the route of delivery, and the underlying rhythm problem, but the effect is consistent enough that diltiazem is a first-line choice in emergency departments for bringing a dangerously fast heart rate under control.

How Diltiazem Slows the Heart

Your heart’s rhythm depends on calcium ions flowing into cardiac cells through tiny protein channels called L-type calcium channels. When calcium enters, it triggers the electrical signals that tell muscle cells to contract and helps propagate the impulse from the upper chambers to the lower ones. Diltiazem sits in these channels and speeds up their inactivation, reducing how much calcium gets through during each heartbeat.¹ The effect is “use-dependent,” meaning the faster the heart beats, the more channels diltiazem manages to block. This is a useful property because it makes the drug particularly effective when the heart is racing.

The AV node, the electrical gateway between the atria and ventricles, is especially sensitive to calcium channel blockade because its cells rely heavily on calcium currents for conduction. By slowing conduction through this gateway, diltiazem reduces the rate at which electrical impulses reach the ventricles. The result is a slower, more controlled ventricular rate even when the atria are firing chaotically, as they do in atrial fibrillation.

In laboratory studies on isolated hearts, diltiazem produced dose-dependent slowing of the heart’s spontaneous rate, though it required roughly twice the concentration of verapamil (another non-dihydropyridine calcium channel blocker) to achieve the same degree of slowing.² That difference matters less in real patients, where diltiazem’s balance of rate control, blood pressure lowering, and tolerability has made it one of the most widely prescribed drugs in this class.

Atrial Fibrillation and Rapid Ventricular Rate

The most common reason doctors use diltiazem for heart rate control is atrial fibrillation (AF) with a rapid ventricular response, meaning the ventricles are beating too fast because of disorganized electrical signals from the atria. In an emergency department study, intravenous diltiazem brought half of patients below a target heart rate of 100 beats per minute within five minutes, and nearly all patients hit that target by 30 minutes.³ That speed of action is one reason diltiazem is a go-to choice in acute settings.

The drug works for rate control in both atrial fibrillation and atrial flutter, a related rhythm where the atria beat in a rapid but organized pattern. In both cases, the goal is not to fix the underlying abnormal atrial rhythm but to prevent those rapid signals from driving the ventricles too fast. By putting the brakes on AV node conduction, diltiazem lets the ventricles beat at a manageable pace while the underlying rhythm problem is addressed separately.

Diltiazem Versus Beta-Blockers

Beta-blockers like metoprolol are the main alternative to diltiazem for acute rate control, and comparing the two is one of the more studied questions in emergency cardiology. In randomized trials, intravenous diltiazem has consistently shown faster and more reliable heart rate reduction than intravenous metoprolol. A meta-analysis pooling data from both randomized and observational studies found that in the randomized trials, patients receiving IV diltiazem were roughly four to five times more likely to achieve rate control than those getting IV metoprolol.⁴ That advantage was not seen in observational studies, which the authors attributed to the messier, less controlled nature of real-world data.

From a safety standpoint, the meta-analysis found no significant difference in hypotension rates between the two drugs.⁴ This matters because low blood pressure is the complication clinicians worry about most when aggressively lowering heart rate. The individual emergency department trial echoed this: neither drug caused more episodes of dangerously low blood pressure or excessive heart rate slowing than the other.³

The picture gets more complicated in intensive care units, though. A recent study emulating a clinical trial using ICU records found that metoprolol was actually associated with better early rate control than diltiazem in critically ill patients, and that diltiazem-treated patients were more likely to need additional medications within six hours.⁵ The authors cautioned that these findings were hypothesis-generating rather than definitive, given the limitations of electronic health record data. Still, it suggests that the choice between diltiazem and beta-blockers can shift depending on the clinical setting and the patient’s overall condition.

Diltiazem Versus Verapamil

Within the calcium channel blocker family, verapamil is the other drug that slows heart rate meaningfully. The two are often considered interchangeable for rate control, and a direct comparison at one medical center largely supported that impression. Both drugs achieved similar rates of heart rate reduction below 110 beats per minute when given as continuous IV infusions: about 90% of patients in the diltiazem group and 89% in the verapamil group hit that target.⁶ Rates of excessive heart rate slowing (bradycardia) were nearly identical between the groups as well.

In practice, diltiazem tends to be preferred in many U.S. hospitals simply because of greater familiarity, established protocols, and available dosing forms. Verapamil is sometimes chosen for patients with specific coexisting conditions or for those who have not responded to diltiazem. The clinical difference between them, at least for rate control, appears to be small.

Converting Supraventricular Tachycardia

Beyond simply slowing a fast heart rate, diltiazem can sometimes break certain abnormal rhythms outright and restore a normal sinus rhythm. This is best documented for supraventricular tachycardia (SVT), a group of fast rhythms that originate above the ventricles and typically involve the AV node as part of a re-entrant circuit. By blocking conduction through the AV node, diltiazem can interrupt the circuit and terminate the episode.

In a dose-finding study, intravenous diltiazem converted SVT to normal rhythm in a dose-dependent fashion. At the lowest dose tested, conversion rates were comparable to placebo, around 25 to 29 percent. But at moderate doses, conversion rates climbed to about 84 percent, and a slightly higher dose achieved 100 percent conversion in the patients studied.⁷ The drug also lengthened the AV node’s refractory period, which is the recovery time before it can conduct another impulse, making it harder for the abnormal circuit to sustain itself.

Adenosine is usually the first drug tried for acute SVT because it works within seconds, but diltiazem serves as an effective backup when adenosine fails. A clinical review noted that in patients who did not convert with adenosine, about 95 percent converted after diltiazem was administered.⁸ Diltiazem also has the advantage of a longer duration of action, which can help prevent immediate recurrence of the arrhythmia after conversion.

Intravenous Versus Oral Diltiazem

When someone arrives in an emergency department with a heart rate of 150 or 160, the usual approach is an IV bolus of diltiazem for immediate rate control, sometimes followed by a continuous IV drip to maintain the effect. Once the rate is controlled, the transition to oral diltiazem allows the patient to be managed without an IV line. But which route actually works better for sustained rate control has been less clear than you might expect.

A retrospective study compared patients started on an IV continuous drip against those switched to oral immediate-release diltiazem tablets. The oral group actually had a lower rate of treatment failure: about 27 percent versus 46 percent for the IV infusion group. After adjusting for differences between patients, oral diltiazem was associated with roughly 60 percent lower odds of failing to maintain rate control.⁹ The authors speculated that the oral formulation’s more predictable absorption and the fact that patients receiving it had already responded to an initial IV bolus contributed to the difference. This does not mean oral is better for the first few minutes of treatment, where speed matters, but it does suggest that keeping someone on a drip longer than necessary is not inherently superior to transitioning to pills.

Heart Rate During Exercise

A common concern with heart rate-lowering drugs is that they might blunt your ability to exercise by preventing the heart from speeding up when your body needs more blood flow. Diltiazem does reduce exercise heart rate, but the effect appears to be well-tolerated. In a study of patients with chronic atrial fibrillation, diltiazem reduced maximum exercise heart rate by about 17 percent (from around 171 to 142 beats per minute) and lowered heart rate during lighter exercise by about 22 percent.¹⁰

Critically, this reduction did not come at the expense of exercise capacity. Oxygen uptake, breathing volume, and blood pressure during exercise were all unchanged. The patients could do the same amount of work with a slower heart rate, likely because the slower rate allowed the heart more time to fill between beats, improving the volume of blood pumped per contraction. For people with atrial fibrillation who want to remain physically active, this is reassuring: diltiazem controls the rate without making exercise feel harder.

Safety Risks and Who Should Avoid Diltiazem

The most predictable side effect of diltiazem is an extension of the very thing it is prescribed to do. If it slows the heart too much, you get bradycardia (an abnormally slow heart rate) or, in rare cases, more serious conduction blocks where electrical signals between the atria and ventricles are delayed or stopped entirely. Sinus arrest and AV block are rare but serious adverse effects.¹¹ The risk goes up when diltiazem is combined with beta-blockers, since both drug classes slow AV conduction through complementary mechanisms. That combination is sometimes used deliberately for stubborn rate control, but it requires careful monitoring.

Diltiazem is generally avoided in patients with heart failure with reduced ejection fraction, meaning the heart muscle has weakened and pumps less efficiently. Because diltiazem reduces the force of cardiac contraction in addition to slowing heart rate, it can worsen heart failure symptoms. A study examining outcomes after hospitals implemented an alert system to flag inappropriate diltiazem use found that patients with reduced ejection fraction who received diltiazem despite the alert were at increased risk of clinical deterioration.¹² This is an important distinction: heart failure with preserved ejection fraction (where the heart pumps strongly but fills poorly) is not necessarily a contraindication, but reduced ejection fraction is a clear one.

Other situations where diltiazem is typically avoided include pre-existing significant conduction disease (like second- or third-degree AV block without a pacemaker), very low blood pressure, and Wolff-Parkinson-White syndrome, a condition involving an accessory electrical pathway in the heart. In WPW, slowing the AV node can paradoxically allow more impulses to travel down the abnormal pathway, potentially causing a dangerously fast ventricular rate.

Drug Interactions Worth Knowing

Diltiazem is metabolized by and also inhibits the liver enzyme CYP3A4, one of the most important enzymes for breaking down medications. This creates a two-way problem. Other drugs that inhibit CYP3A4 (like certain antibiotics) can raise diltiazem levels and intensify its heart-slowing effect. And diltiazem itself can raise levels of other drugs metabolized by the same enzyme.

Research into the specifics of this inhibition has shown that both diltiazem and its primary metabolite, N-desmethyldiltiazem, contribute to CYP3A4 blockade through both reversible and irreversible mechanisms.¹³ The irreversible component is particularly important because it means the enzyme is permanently disabled and the body has to make new enzyme molecules to restore normal drug metabolism. This can keep drug levels elevated for days even after diltiazem is stopped.

In practical terms, some of the most clinically significant interactions include:

Statins: Simvastatin and lovastatin levels can rise sharply when taken with diltiazem, increasing the risk of muscle damage. Many prescribers either cap the statin dose or switch to a less-affected statin.
Cyclosporine: Diltiazem can substantially raise cyclosporine levels, requiring close monitoring in transplant patients.
Digoxin: Another drug used for rate control in AF, digoxin levels climb when diltiazem is added, sometimes enough to cause toxicity.

If you are on diltiazem and a new medication is prescribed, it is always worth checking for CYP3A4 interactions, and any pharmacist can do this quickly.

Extended-Release Formulations

Immediate-release diltiazem is typically dosed three or four times a day, which can be inconvenient for long-term use. Extended-release formulations address this by using polymer-coated pellets or matrix tablets that release the drug gradually over 12 to 24 hours, allowing once- or twice-daily dosing.¹⁴ These formulations are designed to maintain steadier blood levels throughout the day, avoiding the peaks and troughs that come with multiple daily doses.

For heart rate control, the extended-release versions have largely replaced immediate-release tablets as the maintenance formulation. A clinical review found that a daily dose of 360 mg in extended-release form was particularly effective for sustained rate reduction.⁸ Immediate-release tablets still have a role during initial dose titration or in the hospital during the transition from IV to oral therapy, but for chronic outpatient use, the extended-release capsule is the standard.

When Diltiazem Is Not Enough on Its Own

Some patients need more rate control than diltiazem alone can provide. This is especially common in chronic atrial fibrillation where the ventricular rate remains stubbornly elevated despite escalating doses. Adding a second rate-control agent is standard practice in these cases, though combining diltiazem with a beta-blocker carries the risks discussed earlier and requires careful dose adjustment.

Data from veterinary cardiology offers an interesting parallel. In dogs with atrial fibrillation treated with diltiazem, amiodarone, or the combination, both individual drugs reduced the ventricular rate but most animals did not achieve strict rate control with either drug alone. The combination lowered the median daily heart rate by about 43 beats per minute from baseline, yet even with two drugs, roughly two-thirds of dogs had not reached strict control targets.¹⁵ While you cannot translate animal doses directly to humans, the pattern resonates with clinical experience: strict heart rate targets are hard to reach in chronic AF, and “good enough” rate control often becomes the practical goal.

In human practice, if diltiazem combined with another agent still fails, or if rate control proves inadequate to relieve symptoms, the conversation shifts toward rhythm control strategies such as cardioversion or catheter ablation, which aim to restore a normal rhythm rather than just slowing the ventricular response.